In the realm of oncogene target validation and dynamics-structure-based targeted drug design, our research focuses on H3K36 methyltransferases (KMTs) and transcription factors belonging to the BTB family. Through our investigations on KMTs, we have made significant contributions in the field of lung cancer by identifying novel oncogenes, their recurrent missense mutations, and elucidating the molecular bases of their hyperactivity that drive cancerous transformations. Our work extends to the development of selective inhibitors and degraders that specifically target these oncogenic mutations.

Furthermore, our approach incorporates a multidisciplinary strategy, harnessing the power of dynamics and integrated structural biology techniques, including NMR, X-ray crystallography, cryo-electron microscopy, and computational modeling. By employing these methods, we aim to uncover and target cryptic binding sites, thus providing opportunities to tackle otherwise regarded "undruggable" cancer-related proteins, like BTB transcription factors. Our research contributes to the advancement of precision medicine, offering new avenues for therapeutic interventions in oncology.